Update on the changing epidemiology of Clostridium difficile-associated disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 1, 2008, Pages 40-48

  McFarland, Lynne V ^a,b  

^a Puget Sound VA Health Care System   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FUSIDIC ACID; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; POLYMER; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TOLEVAMER; VANCOMYCIN;

BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMMUNICABLE DISEASE; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EPIDEMIC; EVIDENCE BASED MEDICINE; FUNGEMIA; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION CONTROL; LACTOBACILLUS RHAMNOSUS; LENGTH OF STAY; LOW DRUG DOSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SACCHAROMYCES BOULARDII;

ANTI-BACTERIAL AGENTS; CANADA; CLOSTRIDIUM DIFFICILE; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; FLUOROQUINOLONES; HUMANS; RISK FACTORS; UNITED STATES;

EID: 38049084783     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1029     Document Type: Review

References (74)

1. Berrington A et al. (2004) National Clostridium difficile standards group: Report to the Department of Health. J Hosp Infect 56: 1-38
2. McFarland LV et al. (2007) Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35: 237-253
3. Cloud J and Kelly CP (2007) Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 23: 4-9
4. McDonald LC et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441
5. McDonald LC et al. (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415
6. Loo VG et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium-difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353: 2442-2449
7. McFarland LV et al. (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320: 204-210
8. McMaster-Baxter NL and Musher DM (2007) Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 27: 1029-1039
9. Rupnik M et al. (2005) Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 54 113-117
10. Geric B et al. (2004) Distribution of Clostridlum difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53: 887-894
11. Goncalves C et al. (2004) Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 42: 1933-1939
12. McDonald LC et al.; Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28: 140-145
13. Rupnik M et al. (2003) New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 41: 1118-1125
14. Delmee M et al. (2005) Laboratory diagnosis of Clostridium difficile-associated diarrhoea: A plea for culture. J Med Microblol 54: 187-191
15. Gerding DN (2007) New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile. Infect Control Hosp Epidemiol 28: 113-115
16. Cookson B (2007) Hypervirulent strains of Clostridium difficile. Postgrad Med J 83: 291-295
17. Pepin J et al. (2004) Clostridium difficile-associated diarrhea in a region of Québec from 1991 to 2003: A changing pattern of disease severity. CMAJ 171: 466-472
18. Pepin J et al. (2005) Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173: 1037-1042
19. MacCannell DR et al. (2006) Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44: 2147-2152
20. Warny M et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084
21. Kuijper EJ et al. (2007) Clostridium difficile: Changing epidemiology and new treatment options. Curr Opin Infect Dis 20 376-383
22. Hubert B et al. (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 44, 238-244
23. Musher DM et al. (2006) Epidemic Clostridium difficile. N Engl J Med 354: 1199-1203
24. Kuijper EJ et al. (2007) Update of Clostridium, difficile associated disease due to PCR ribotype 027 in Europe. Euro Surveill 12: E1-E2
25. van Steenbergen J et al. (2005) Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile-associated diarrhoea. Euro Surveill 10: E050714.1
26. Kuijper EJ et al.; ESCMID Study Group for Clostridium difficile EU Member States; European Centre for Disease Prevention and Control (2006) Emergence of Clostridium, difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6): S2-S18
27. Delmee M et al. (2006) Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006. Euro Surveill 11: E060914.2
28. Kato H et al. (2007) First isolation of Clostridrum difficile 027 in Japan. Euro Surveill 12: E070111.3
29. Tachon M et al. (2006) First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Euro Surveill 11: E060504.1
30. Biller P et al. (2007) Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28: 198-201
31. Coignard B et al. (2006) Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Euro Surveill 11: E060914.1
32. Kazakova SV et al. (2006) A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 166: 2518-2524
33. Rodriguez-Palacios A et al. (2006) Clostridium difficile PCR ribotypes in calves, Canada. Emerg Infect Dis 12: 1730-1736
34. Drudy D et al. (2007) Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 28: 932-940
35. McFarland LV et al. (2007) Fluoroquinolone use and risk factors for Clostridium difficile disease within a Veterans Administration Health Care System. Clin. Infect Dis 45: 1141-1151
36. Clabots CR et al. (1992) Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J Infect Dis 166: 561-567
37. Shim JK et al. (1998) Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351: 633-636
38. Terhes G et al. (2004) Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 42: 4316-4318
39. Beaugerie L et al. (2003) Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther 17:905-912
40. Centers for Disease Control (2005) Severe Clostridium difficile associated disease in populations previously at low risk- four states, 2005. MMWR Morb Mortal Wkly Rep 54:1201-1205
41. Dial S et al. (2006) Proton pump inhibitor use and risk of community-acquired Clostadium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175: 745-748
42. Lefebvre SL et al. (2006) Prevalence of zoonotic agents in dogs visiting hospitalized people in Ontario: Implications for infection control. J Hosp Infect 62: 458-466
43. Dial S et al. (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989-2995
44. Kyne L et al. (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 357:189-193
45. McFarland LV et al. (2000) Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gastroenterol Nutr 31. 220-231
46. Morinville V and McDonald J (2005) Clostridium difficile associated diarrhea in 200 Canadian children. Can J Gastroenterol 19:497-501
47. Gogate A et al. (2005) Diagnostic role of stool culture & toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian J Med Res 122: 518-524
48. Gaynes R et al. (2004) Outbreak of Clostridiurn difficile infection in a long-term care facility: Association with gatifloxacin use. Clin Infect Dis 38: 640-645
49. Pepin J et al. (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 41: 1254-1260
50. Johnson S et al. (1990) Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 88:137-140
51. Gerding et al. (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16: 459-477
52. Boone N et al. (1998) Evaluation of an interdisciplinary re-isolation policy for patients with previous Clostridium difficile diarrhea. Amer J Infect Control 26: 584-587
53. McMullen KM et al. (2007) Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 28: 205-207
54. Sehulster L and Chinn RY (2003) Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52:1-42
55. Jernigan JA et al. (1998) A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 19: 494-499
56. Davey P et al. (2005) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systemetic Reviews 2005, Issue 4. Art. No.: CDO03543. doi:10.1002/ 14651858.CD003543.pub2
57. Dellit TH et al.; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159-177
58. Valiquette L et al. (2007) Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease cause by the hypervirulent NAP1/027 Strain. Clin Infect Dis 45 (Suppl 2): S112-S121
59. Sunenshine RH and McDonald LC (2006) Clostridium difficile associated disease: New challenges from an established pathogen. Cleveland Clinic J Med 73: 187-197
60. Apisamthanarak A et al. (2004) Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin Infect Dis 39: 601-602
61. Owens RC Jr and Rice L (2006) Hospital-based strategies for combating resistance. Clin Infect Dis 42 (Suppl 4): S173-S181
62. Zar FA et al. (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridiurn difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302-307
63. McFarland LV et al. (2002) Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97: 1769-1775
64. Teasley DG et al. (1983) Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis. Lancet 2: 1043-1046
65. Wenisch C et al. (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22: 813-818
66. Pepin J et al. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Québec, Canada. Clin infect Dis 40: 1591-1597
67. Musher D et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40: 1586-1590
68. Lagrotteria D et al. (2006) Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 43: 547-552
69. Pelaez T et al. (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46: 647-1650
70. Louie TJ et al. (2006) Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile associated diarrhea. Clin Infect Dis 43: 411-420
71. Elmer GW et al. (2007) AAD and Clostridium difficile disease. In The Power of Probiotics: Improving Your Health with Beneficial Microbes 71-93 (Eds Elmer GE, McFarland LV, McFarland MJ) Binghamton, NY: Haworth Press
72. Surawicz CM et al. (2000) The search for a better treatment for recurrent Clostridium, difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardil. Clin Infect Dis 31: 1012-1017
73. McFarland LV et al. (2006) Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-822
74. Mulligan ME et al. (1993) Electated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 16 (Suppl 4): S239-S244